Open access
Open access
Powered by Google Translator Translator

Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.

26 May, 2022 | 10:30h | UTC

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.